B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality

R. M. Saliba, S. Sarantopoulos, C. L. Kitko, A. Pawarode, S. C. Goldstein, J. Magenau, A. M. Alousi, T. Churay, H. Justman, Sophie Paczesny, P. Reddy, D. R. Couriel

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Biological markers for risk stratification of chronic GvHD (cGvHD) could improve the care of patients undergoing allogeneic hematopoietic stem cell transplantation. Increased plasma levels of B-cell activating factor (BAFF), chemokine (C-X-C motif) ligand 9 (CXCL9) and elafin have been associated with the diagnosis, but not with outcome in patients with cGvHD. We evaluated the association between levels of these soluble proteins, measured by ELISA at the time of cGvHD diagnosis and before the initiation of therapy, with non-relapse-mortality (NRM). Based on the log-transformed values, factor levels were divided into tertiles defined respectively as low, intermediate, and high levels. On univariable analysis, BAFF levels were significantly associated with NRM, whereas CXCL9 and elafin levels were not. Both low (' 1/22.3 ng/mL, hazard ratio (HR)=5.8, P=0.03) and high (>5.7 ng/mL, HR=5.4, P=0.03) BAFF levels were associated with a significantly higher NRM compared with intermediate BAFF level. The significant effect of high or low BAFF levels persisted in multivariable analysis. A subset of cGvHD patients had persistently low BAFF levels. In conclusion, our data show that BAFF levels at the time of cGvHD diagnosis are associated with NRM, and also are potentially useful for risk stratification. These results warrant confirmation in larger studies.

Original languageEnglish (US)
Pages (from-to)1010-1015
Number of pages6
JournalBone Marrow Transplantation
Volume52
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

B-Cell Activating Factor
Elafin
Mortality
Ligands
CXC Chemokines
Hematopoietic Stem Cell Transplantation
Patient Care
Biomarkers
Enzyme-Linked Immunosorbent Assay
Proteins

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Saliba, R. M., Sarantopoulos, S., Kitko, C. L., Pawarode, A., Goldstein, S. C., Magenau, J., ... Couriel, D. R. (2017). B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. Bone Marrow Transplantation, 52(7), 1010-1015. https://doi.org/10.1038/bmt.2017.73

B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. / Saliba, R. M.; Sarantopoulos, S.; Kitko, C. L.; Pawarode, A.; Goldstein, S. C.; Magenau, J.; Alousi, A. M.; Churay, T.; Justman, H.; Paczesny, Sophie; Reddy, P.; Couriel, D. R.

In: Bone Marrow Transplantation, Vol. 52, No. 7, 01.07.2017, p. 1010-1015.

Research output: Contribution to journalArticle

Saliba, RM, Sarantopoulos, S, Kitko, CL, Pawarode, A, Goldstein, SC, Magenau, J, Alousi, AM, Churay, T, Justman, H, Paczesny, S, Reddy, P & Couriel, DR 2017, 'B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality', Bone Marrow Transplantation, vol. 52, no. 7, pp. 1010-1015. https://doi.org/10.1038/bmt.2017.73
Saliba, R. M. ; Sarantopoulos, S. ; Kitko, C. L. ; Pawarode, A. ; Goldstein, S. C. ; Magenau, J. ; Alousi, A. M. ; Churay, T. ; Justman, H. ; Paczesny, Sophie ; Reddy, P. ; Couriel, D. R. / B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. In: Bone Marrow Transplantation. 2017 ; Vol. 52, No. 7. pp. 1010-1015.
@article{6e6c182e84f0458ba208def7b142f16e,
title = "B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality",
abstract = "Biological markers for risk stratification of chronic GvHD (cGvHD) could improve the care of patients undergoing allogeneic hematopoietic stem cell transplantation. Increased plasma levels of B-cell activating factor (BAFF), chemokine (C-X-C motif) ligand 9 (CXCL9) and elafin have been associated with the diagnosis, but not with outcome in patients with cGvHD. We evaluated the association between levels of these soluble proteins, measured by ELISA at the time of cGvHD diagnosis and before the initiation of therapy, with non-relapse-mortality (NRM). Based on the log-transformed values, factor levels were divided into tertiles defined respectively as low, intermediate, and high levels. On univariable analysis, BAFF levels were significantly associated with NRM, whereas CXCL9 and elafin levels were not. Both low (' 1/22.3 ng/mL, hazard ratio (HR)=5.8, P=0.03) and high (>5.7 ng/mL, HR=5.4, P=0.03) BAFF levels were associated with a significantly higher NRM compared with intermediate BAFF level. The significant effect of high or low BAFF levels persisted in multivariable analysis. A subset of cGvHD patients had persistently low BAFF levels. In conclusion, our data show that BAFF levels at the time of cGvHD diagnosis are associated with NRM, and also are potentially useful for risk stratification. These results warrant confirmation in larger studies.",
author = "Saliba, {R. M.} and S. Sarantopoulos and Kitko, {C. L.} and A. Pawarode and Goldstein, {S. C.} and J. Magenau and Alousi, {A. M.} and T. Churay and H. Justman and Sophie Paczesny and P. Reddy and Couriel, {D. R.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1038/bmt.2017.73",
language = "English (US)",
volume = "52",
pages = "1010--1015",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality

AU - Saliba, R. M.

AU - Sarantopoulos, S.

AU - Kitko, C. L.

AU - Pawarode, A.

AU - Goldstein, S. C.

AU - Magenau, J.

AU - Alousi, A. M.

AU - Churay, T.

AU - Justman, H.

AU - Paczesny, Sophie

AU - Reddy, P.

AU - Couriel, D. R.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Biological markers for risk stratification of chronic GvHD (cGvHD) could improve the care of patients undergoing allogeneic hematopoietic stem cell transplantation. Increased plasma levels of B-cell activating factor (BAFF), chemokine (C-X-C motif) ligand 9 (CXCL9) and elafin have been associated with the diagnosis, but not with outcome in patients with cGvHD. We evaluated the association between levels of these soluble proteins, measured by ELISA at the time of cGvHD diagnosis and before the initiation of therapy, with non-relapse-mortality (NRM). Based on the log-transformed values, factor levels were divided into tertiles defined respectively as low, intermediate, and high levels. On univariable analysis, BAFF levels were significantly associated with NRM, whereas CXCL9 and elafin levels were not. Both low (' 1/22.3 ng/mL, hazard ratio (HR)=5.8, P=0.03) and high (>5.7 ng/mL, HR=5.4, P=0.03) BAFF levels were associated with a significantly higher NRM compared with intermediate BAFF level. The significant effect of high or low BAFF levels persisted in multivariable analysis. A subset of cGvHD patients had persistently low BAFF levels. In conclusion, our data show that BAFF levels at the time of cGvHD diagnosis are associated with NRM, and also are potentially useful for risk stratification. These results warrant confirmation in larger studies.

AB - Biological markers for risk stratification of chronic GvHD (cGvHD) could improve the care of patients undergoing allogeneic hematopoietic stem cell transplantation. Increased plasma levels of B-cell activating factor (BAFF), chemokine (C-X-C motif) ligand 9 (CXCL9) and elafin have been associated with the diagnosis, but not with outcome in patients with cGvHD. We evaluated the association between levels of these soluble proteins, measured by ELISA at the time of cGvHD diagnosis and before the initiation of therapy, with non-relapse-mortality (NRM). Based on the log-transformed values, factor levels were divided into tertiles defined respectively as low, intermediate, and high levels. On univariable analysis, BAFF levels were significantly associated with NRM, whereas CXCL9 and elafin levels were not. Both low (' 1/22.3 ng/mL, hazard ratio (HR)=5.8, P=0.03) and high (>5.7 ng/mL, HR=5.4, P=0.03) BAFF levels were associated with a significantly higher NRM compared with intermediate BAFF level. The significant effect of high or low BAFF levels persisted in multivariable analysis. A subset of cGvHD patients had persistently low BAFF levels. In conclusion, our data show that BAFF levels at the time of cGvHD diagnosis are associated with NRM, and also are potentially useful for risk stratification. These results warrant confirmation in larger studies.

UR - http://www.scopus.com/inward/record.url?scp=85021836696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021836696&partnerID=8YFLogxK

U2 - 10.1038/bmt.2017.73

DO - 10.1038/bmt.2017.73

M3 - Article

C2 - 28481353

AN - SCOPUS:85021836696

VL - 52

SP - 1010

EP - 1015

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -